Welcome to BioSeeker Group!

Triple Analysis: Prostate Cancer, Angiogenesis and Peptides

Additional Information

Published Date Jan 7, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 4210
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Prostate Cancer, Angiogenesis and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Prostate Cancer), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Peptides).

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Prostate Cancer, Angiogenesis and Peptides.

    To find out more about Triple Analysis: Prostate Cancer, Angiogenesis and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Prostate Cancer, Angiogenesis and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Prostate Cancer), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Peptides). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Prostate Cancer
The prostate cancer drug report part comprises defined and up to date development strategies for 394 drugs within the portfolio of 222 companies world-wide, from Ceased to Marketed. The report extensively analyses their 227 identified drug targets, organized into 216 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Competitive Handbook towards Personalized Medicine in Prostate Cancer

Part II: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Prostate Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Prostate Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (227 Drug Targets) 35-437
7 Emerging New Products to Established Ones: Drug Target Strategies of Prostate Cancer Drugs by their Highest Stage of Development (216 Drug Target Strategies and 394 Drugs) 438-699
8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-748
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Prostate Cancer Drug Pipeline by Investigator (222 Investigators and 394 Drugs) 749-1470
10 Disclaimer 1471
Figures: Includes 8 Figures
Tables: Includes 283 Tables
Total Number of Pages: 1,493

Part II: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
7TM Pharma
Abbott
Acceleron Pharma
Access
Active Biotech
Adherex
Advantagene
Advaxis
Advenchen
AEgera
AEterna Zentaris
Affymax
Agennix
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Alchemia
Alethia Biotherapeutics
Allos Therapeutics
Allostera
Allosterix
Alnylam
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
American Gene Technology International
Amgen
Amphora
Anavex Life Sciences
Anchor Therapeutics
AndroBioSys
AngioChem
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisense Pharma
Antisense Therapeutics
Antisoma
Aphios
AplaGen Biopharmaceuticals
ApopLogic Pharmaceuticals
Apotex
Aprea
Arana Therapeutics
Ardana
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Ascepion Pharmaceuticals
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
AVI BioPharma
Bavarian Nordic
Baxter International
Bayer
Bellicum Pharmaceuticals
BioAlliance Pharma
BioAxone
Biocad
Bioenvision
Biogen Idec
Biokine Therapeutics
BioLineRx
BioMarin
BioNetWorks
BioSante
Biostar
Boehringer Ingelheim
Bolder BioTechnology
Bristol-Myers Squibb
BTG
Camurus
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Cel-Sci
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Cellmid
Celsion
Center of Molecular Immunology
Cephalon
ChemoCentryx
Chemokine Therapeutics
Chiasma
China Sky One Medical
Choongwae
Circadian Technologies
Cleveland BioLabs
Clinuvel
Colby
Compugen
Cosmo Bioscience
Cue Biotech
Curaxis
Curis
Cyclacel
Cylene Pharmaceuticals
Cytochroma
Cytokinetics
Daiichi Sankyo
Debiopharm
Deciphera Pharmaceuticals
Dendreon
Digna Biotech
Dongkook Pharm
Dyax
ECI
Eisai
Eli Lilly
Endo Pharmaceuticals
Endocyte
Enkam Pharmaceuticals
Ensemble Discovery
EntreMed
EpiCept
Esperance Pharmaceuticals
Etubics
EUSA Pharma
Exelixis
ExonHit Therapeutics
Ferring
Five Prime Therapeutics
Formula Pharmaceuticals
Galena Biopharma
GammaCan
Gemin X Pharmaceuticals
Generex
Genmab
GENova Biotherapeutics
Genovax
Genta
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GlycoGenesys
Got-a-Gene
GP Pharm
Green Cross
Gryphon Therapeutics
GTx
Harbor BioSciences
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Idera Pharmaceuticals
IGF Oncology
ImClone Systems
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
Immunotope
ImmuPharma
Incyte Corporation
Infinity Pharmaceuticals
Innovive
Inovio
Insmed
Insys Therapeutics
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
Ivy Medical Chemicals
Johnson & Johnson
KAEL-GemVax
KAI Pharmaceuticals
Karo Bio
Karus Therapeutics
Karyon-CTT
Kinex
Kirax
Kirin Pharma
Kringle Pharma
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
Ligand
Lorus Therapeutics
Mannkind
Marillion Pharmaceuticals
MAT Biopharma
MBiotec
Med Discovery
Meda
Medarex
MediGene
MedImmune
Mediolanum
Medivation
Menarini
Merck & Co
Merck KGaA
Merrion Pharmaceuticals
Mersana Therapeutics
MethylGene
Micromet
Mojave Therapeutics
Molecular Insight
MolMed
Morvus Technology
Nektar Therapeutics
Nemod Biotherapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurobiological Technologies
Neurocrine Biosciences
NewSouth Innovations
Nidus Laboratories
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
Novartis
Novelix
Novogen
Noxxon
NPS Pharmaceuticals
Oasmia
OncoGenex Pharmaceuticals
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Orion Pharma
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
Pantarhei Bioscience
Pepscan Therapeutics
Peptagen
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmacopeia
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Pharminox
Philogen
PhiloGene
Pierre Fabre
Progen
Progenics Pharmaceuticals
ProNAi Therapeutics
ProStrakan
Protagonist
Protein Sciences
Protgen
PTC Therapeutics
Q Chip
QLT
Raptor Pharmaceutical
Receptor BioLogix
Regeneron
Regulon
Rexahn
Rigel
Salzburg Therapeutics
Samyang
Sanofi
Santaris Pharma
Sapphire Therapeutics
Sarepta Therapeutics
SBIO
Scancell
SciClone Pharmaceuticals
SeleXel
Semafore Pharmaceuticals
Serometrix
SGX Pharmaceuticals
Shionogi
Shire
Siena Biotech
Simcere Pharmaceuticals
Soligenix
Sophiris Bio
Spear Therapeutics
Spectrum Pharmaceuticals
SRI International
Stainwei Biotech
SuperGen
Supratek Pharma
Switch Pharma
SynDevRx
Synta Pharmaceuticals
Tactic Pharma
Taiho
Takeda
Tapestry Pharmaceuticals
Tau Therapeutics
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
Tokai Pharmaceuticals
ToolGen
TopoTarget
Tracon Pharmaceuticals
Transgene
Twinstrand Therapeutics
UCB
Unigene
United Biomedical
Vaxil BioTherapeutics
Vaxon Biotech
VBL Therapeutics
Velacor Therapeutics
Vical
Wilex
Vion Pharmaceuticals
VioQuest
Viralytics
ViroTarg
VM Discovery
Xerion
Xigen
Xoma
YM BioSciences
Zelos Therapeutics
Zensun
Zydus Cadila
A Shortlist of Drugs Included are:
A6
abarelix
abiraterone acetate
ABT-510
adecatumumab
aderbasib
AEZS-108
afamelanotide
afatinib
aflibercept
ALT-801
alvocidib
AMG-386
amonafide dihydrochloride
amonafide malate
angiopep+paclitaxel
Angiozyme
apatinib
APC-100
APR-246
ARC-100
ARQ-197
atrasentan
AVX-701
axitinib
bafetinib
bevacizumab
BIBF-1120
bicalutamide
BMS-690514
BMS-777607
BMS-936558
bortezomib
BP-GMAX-CD1
brivanib alaninate
buserelin
Cabozantinib
carlumab
CBP-501
cediranib
celecoxib
cetuximab
cilengitide
cixutumumab
corticorelin acetate
custirsen
danusertib
dasatinib
DCVax-prostate
degarelix
denosumab
deslorelin
DI-17E6
docetaxel
dovitinib lactate
doxercalciferol
doxorubicin
dutasteride
E-75
E-7820
emepepimut-S
endostatin
ENMD-2076
entinostat
enzastaurin hydrochloride
EP-100
estramustine phosphate sodium
ethinyl estradiol sulfonate
everolimus
Exherin
figitumumab
flutamide
foretinib
fosbretabulin tromethamine
FPI-01
fulvestrant
gataparsen
GDC-0980
gefitinib
GliaAtak
goserelin
GT-111
GTx-758
GV-1001
GVAX
GVX-3322
GX-301
HBP-347
HE-3235
Her-2/Neu peptides
histrelin
icrucumab
idronoxil
imatinib mesilate
imMucin
inecalcitol
INSM-18
interleukins
intetumumab
ipilimumab
IPP-204106
irosustat
ISA-P53-01
ispinesib mesylate
JI-101
kahalalide F
KX2-391
lanreotide
lapatinib ditosylate
lenvatinib
lestaurtinib
leucine-doxorubicin
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
leuprorelin acetate
linifanib
LIP-131I
LipoVIL12
litronesib
LOR-2040
LOR-2501
LY-2275796
MCS-110
MDV-3100
MDX-1379
MGCD-265
midostaurin
MLN-8237
motesanib diphosphate
muparfostat (IV)
Nab-docetaxel
nadroparin
NAFB001
netupitant
NGR-TNF
nilutamide
nimotuzumab
oblimersen sodium
octreotide
octreotide, LAR
OGX-427
olaparib
olaratumab
ON-01910
orteronel
OTS-102
ozarelix
paclitaxel
paclitaxel polyglumex
PancAtak
panitumumab
panobinostat
pasireotide
pasireotide LAR
pazopanib hydrochloride
PCI-27483
pegdinetanib
perifosine
pertuzumab
PF-4856884
plitidepsin
PLX-3397
polyclonal antibody stimulator
ponatinib
ProstAtak
PROSTVAC
PRX-302
PTC-299
PX-866
quarfloxacin
quinacrine
R-(-)-gossypol
RAF-265
ramucirumab
regorafenib
retaspimycin
ridaforolimus
rilotumumab
rindopepimut
romidepsin
romurtide
ruxolitinib
sagopilone
sargramostim
SB-939
siltuximab
sipuleucel-T
sirolimus
sorafenib tosylate
sotatercept
SU-6668
sunitinib malate
Survivac
TAK-448
talactoferrin alfa
tandutinib
TAS-102
tasquinimod
TB-403
telatinib
temsirolimus
Tenarad
thymalfasin
tipifarnib
tivozanib
TM-30339
TOK-001
toremifene citrate
TRC-105
tremelimumab
trilostane
triptorelin
TroVax
TS-1
tucotuzumab celmoleukin
vandetanib
vapreotide, immediate-release
vismodegib
vitespen
volociximab
VX-001
XL-184
XL-647
YM-155
zibotentan

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Prostate Cancer, Angiogenesis and Peptides.
    To find out more about Triple Analysis: Prostate Cancer, Angiogenesis and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Prostate Cancer, Angiogenesis and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Leukemia, Melanoma and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Leukemia and Melanoma and by the mechanism/target/effect of Angiogenesis. Learn More


The Drug Target Atlas of Apoptotic Drugs in Oncology
First in place, BioSeeker has surveyed apoptopic drugs in oncology and identified 119 drug targets, belonging to 114 drugs. This report, The Drug Target Atlas of Apoptopic Drugs in Oncology, is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of new apoptopic drugs in oncology. Learn More

Other selected research from the 'Oncology' category:


GnRH Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 185 companies plus partners who are today developing 234 GnRH signaling pathway targeting drugs in 844 developmental projects in cancer across 126 different targets. In addition, there is 1 suspended drug and another 86 drugs where development has been ceased. Learn More


Cancer Immunotherapy: Analytical Tool
This Analytical Tool transforms your computer’s desktop into a high capacity workbench within the area of immuno-oncology. It supports you in making reports, presentations and preparing conference attendance and it is all done via an easy to use ’point and click’ interface. Learn More